Loading...
XNAS
LQDA
Market cap2.94bUSD
Dec 05, Last price  
34.41USD
1D
1.44%
1Q
19.27%
IPO
213.10%
Name

Liquidia Corp

Chart & Performance

D1W1MN
XNAS:LQDA chart
P/E
P/S
210.09
EPS
Div Yield, %
Shrs. gr., 5y
33.61%
Rev. gr., 5y
11.64%
Revenues
14m
-19.97%
13,216,9897,258,1232,706,9818,072,120739,62812,853,34515,935,00017,488,00013,996,000
Net income
-130m
L+66.10%
-15,933,762-29,154,240-53,135,859-46,389,335-57,491,188-29,781,809-38,365,000-78,502,000-130,394,000
CFO
-93m
L+124.77%
-13,946,701-24,290,354-31,830,535-48,282,674-54,144,507-34,035,659-28,588,000-41,564,000-93,422,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
IPO date
Jul 26, 2018
Employees
63
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT